A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients
Phase of Trial: Phase IV
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Eisai Korea
- 12 Mar 2018 Planned End Date changed from 1 May 2018 to 1 Sep 2018.
- 12 Mar 2018 Planned primary completion date changed from 1 May 2018 to 1 Sep 2018.
- 21 Feb 2018 New trial record